Roche: results, outlook and obesity programs
What Roche has reported about its sales and outlook, and what it has said about its obesity medicines. Roche reports in Swiss francs, and the Atlas does not convert them. Every figure is dated and linked to where it came from.
Last checked . Figures are company-reported unless a line says otherwise. This is not investment advice. For a related medicine see the petrelintide page and the pipeline.
The 15.5% and 2.65% are company-reported averages for the 24 mg group, not placebo-adjusted. Roche's releases give no placebo-adjusted figures. Source for the sales figures: Roche's October 22, 2026 release.
First nine months of 2026, reported October 22
Roche reported group sales of CHF 46,493 million for the first nine months, up 6% at constant exchange rates and 1% in Swiss francs (7% in US dollars). In the third quarter, sales rose 7% at constant rates and 8% in Swiss francs, which Roche says reflects exchange rates stabilizing.
| Measure | Nine months 2026 | Nine months 2025 | Change at constant rates | Change in Swiss francs |
|---|---|---|---|---|
| Group sales | CHF 46,493 million | CHF 45,862 million | +6% | +1% |
Source: Roche release, October 22, 2026.
Roche's 2026 outlook
Roche confirmed its outlook for 2026: group sales growth in the mid-single-digit range at constant rates, core earnings per share growth in the high single-digit range at constant rates, and a further dividend increase in Swiss francs.
Enicepatide and petrelintide in the release
Roche's nine-month release lists enicepatide and petrelintide together as phase II programs in overweight or obesity and type 2 diabetes. It gives data for enicepatide and none for petrelintide.
Enicepatide is a dual GLP-1 and GIP receptor agonist. Roche's September 22 release describes the CT-388-104 study (NCT06628362), a randomized, double-blind, placebo-controlled phase II trial in 447 adults with type 2 diabetes and overweight or obesity. Enicepatide was given by injection under the skin for 48 weeks. The release does not give placebo-adjusted results.
| Result at the 24 mg dose | Roche-reported value |
|---|---|
| Mean weight loss at 48 weeks | 15.5%, without a plateau |
| Mean HbA1c reduction at 48 weeks | 2.65%, from a baseline of 8.1% |
| Reached the diabetes target of 6.5% HbA1c or lower | 90% |
| Reached normal blood sugar (HbA1c below 5.7%) | 62% |
The October 22 release does not name the study or give group sizes. Study details come from the September 22 release. For petrelintide, see the Atlas petrelintide page.
Coming up
- First half of 2027: Roche says it plans to start a phase III glycemic-control program and cardiovascular outcomes trials for enicepatide. Two phase III studies in chronic weight management, ENITH-1 and ENITH-2, are already ongoing.
Roche's October 22 release gives no date for its next sales report.
Questions about Roche's results
Did Roche confirm its 2026 outlook?
Yes. Roche expects group sales to grow in the mid-single-digit range at constant exchange rates in 2026, and core earnings per share to grow in the high single-digit range.
What did Roche report for enicepatide?
At the 24 mg dose, mean weight loss of 15.5% at 48 weeks and a mean HbA1c reduction of 2.65% in a phase II trial of 447 adults with type 2 diabetes and overweight or obesity. Roche has not given placebo-adjusted figures in the releases the Atlas read.
Why are the figures in Swiss francs?
Roche reports in Swiss francs. The Atlas shows company figures in the currency the company reports and does not convert them, so Roche cannot be compared directly with the US-dollar companies on the business overview without adjusting for exchange rates.
Sources
- Roche, nine-month 2026 sales and key developments release, October 22, 2026. Company-reported figures.
- Roche, enicepatide phase II results release, September 22, 2026. Company-reported, for study design and the plans for phase III.
- Atlas petrelintide page, for the other medicine named in the release.